NCT00003792View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

April 30, 1999

Study Completion Date

October 31, 2006

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

MART-1 antigen

BIOLOGICAL

filgrastim

BIOLOGICAL

flu matrix peptide p58-66

BIOLOGICAL

gp100 antigen

BIOLOGICAL

recombinant MAGE-3.1 antigen

BIOLOGICAL

tyrosinase peptide

PROCEDURE

in vitro-treated peripheral blood stem cell transplantation

Trial Locations (1)

75246

Baylor University Medical Center, Dallas

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Baylor Health Care System

OTHER